Predictors of Heart Failure in Patients With Stable Coronary Artery Disease: A PEACE Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background— Heart failure (HF) is a disease commonly associated with coronary artery disease. Most risk models for HF development have focused on patients with acute myocardial infarction. The Prevention of Events with Angiotensin-Converting Enzyme Inhibition population enabled the development of a risk model to predict HF in patients with stable coronary artery disease and preserved ejection fraction. Methods and Results— In the 8290, Prevention of Events with Angiotensin-Converting Enzyme Inhibition patients without preexisting HF, new-onset HF hospitalizations, and fatal HF were assessed over a median follow-up of 4.8 years. Covariates were evaluated and maintained in the Cox regression multivariable model using backward selection if P <0.05. A risk score was developed and converted to an integer-based scoring system. Among the Prevention of Events with Angiotensin-Converting Enzyme Inhibition population (age, 64�8; female, 18%; prior myocardial infarction, 55%), there were 268 cases of fatal and nonfatal HF. Twelve characteristics were associated with increased risk of HF along with several baseline medications, including older age, history of hypertension, and diabetes. Randomization to trandolapril independently reduced the risk of HF. There was no interaction between trandolapril treatment and other risk factors for HF. The risk score (range, 0 to 21) demonstrated excellent discriminatory power (c-statistic 0.80). Risk of HF ranged from 1.75% in patients with a risk score of 0% to 33% in patients with risk score ≥16. Conclusion— Among patients with stable coronary artery disease and preserved ejection fraction, traditional and newer factors were independently associated with increased risk of HF. Trandolopril decreased the risk of HF in these patients with preserved ejection fraction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 1×
“Disease (MDRD) equation which includes serum creatinine, sex, age, and race(19).”
BackgroundThe progression from hypertension to congestive heart failure
Levy, D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530440037034 · Cited by 2,155 · cited 1×
“been well-characterized in multiple prediction models(14, 25, 26).”
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14286-9 · Cited by 2,142 · cited 1×
“In HOPE and EUROPA, ACE-inhibition decreased CV risk and mortality(17, 38).”
MethodAssmann, G., Cullen, P., & Schulte, H. (2002) · Circulation · doi:10.1161/hc0302.102575 · Cited by 1,541 · cited 1×
“To validate the final Cox model, we used the methods of Assman, Cullen, and Schulte(22).”
MethodYusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. (2001) · Circulation · doi:10.1161/hc4701.099488 · Cited by 1,141
Angiotensin-converting-enzyme inhibition in stable coronary artery disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa042739 · Cited by 1,123
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure
Hillege, H. L., Nitsch, D., Pfeffer, M. A., Swedberg, K., McMurray, J. J. V., Yusuf, S., Granger, C. B., Michelson, E. L., Östergren, J., Cornel, J. H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.580506 · Cited by 945 · cited 1×
“Lower GFR has previously been shown to be predictive of adverse events in patients with myocardial infarction(29) and chronic HF(30, 31) and has identified patients who may be more likely to benefit from medical interventions(32).”
BackgroundSelf-citationDagenais, G. R., Pogue, J., Fox, K., Simoons, M. L., & Yusuf, S. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69201-5 · Cited by 514 · cited 1×
“Finally, a meta-analysis of HOPE, EUROPA, and PEACE demonstrated consistent reduction in CV events and HF(39).”
MethodPredictors of heart failure among women with coronary disease
Bibbins-Domingo, K., Lin, F., Vittinghoff, E., Barrett-Connor, E., Hulley, S. B., Grady, D., & Shlipak, M. G. (2004) · Circulation · doi:10.1161/01.cir.0000141726.01302.83 · Cited by 171
Hohnloser, S. H., Klingenheben, T., Zabel, M., Schöpperl, M., & Mauß, O. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00108-4 · Cited by 125 · cited 1×
“These patients living with CAD are at higher risk for death and a range of additional cardiovascular outcomes, including recurrent myocardial infarction (MI), arrhythmia, stroke, and heart failure(3-6).”
Background
Cited by
Bozkurt, B., Aguilar, D., Deswal, A., Dunbar, S. B., Francis, G. S., Horwich, T., Jessup, M., Kosiborod, M., Pritchett, A. M., Ramasubbu, K., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000450 · Cited by 522
van Melle, J. P., Bot, M., de Jonge, P., de Boer, R. A., van Veldhuisen, D. J., & Whooley, M. A. (2010) · Diabetes Care · doi:10.2337/dc10-0286 · Cited by 159
Kodama*, S., Fujihara, K., Horikawa, C., Sato, T., Iwanaga, M., Yamada, T., Kato, K., Watanabe, K., Shimano, H., Izumi, T., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12782 · Cited by 63
Lamberts, R. R., Lingam, S. J., Wang, H.-Y., Bollen, I. A., Hughes, G., Galvin, I. F., Bunton, R. W., Bahn, A., Katare, R., Baldi, J., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-72 · Cited by 60
Metadata
- Authors
- Lewis, E. F., Solomon, S. D., Jablonski, K. A., Rice, M. M., Clemenza, F., Hsia, J., Maggioni, A. P., Zabalgoitia, M., Huynh, T., Cuddy, T. E., Gersh, B. J., Rouleau, J., Braunwald, E., & Pfeffer, M. A.
- Venue
- Circulation: Heart Failure
- Published
- 2009-05
- Volume
- 2
- Issue
- 3
- Pages
- 209-216
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W2547346359
- Cited by
- 64
- References
- 10
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.